AACP
PSTX

Advantage Alpha Capital Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Advantage Alpha Capital Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-99,566
Closed -$285K – 183
2024
Q3 		$285K Buy
+99,566
New +$308K 0.06% 159

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Advantage Alpha Capital Partners's PSTX Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 99,566 shares — an estimated $285K sold.

Advantage Alpha Capital Partners first reported a position in PSTX in Q3 2024 and held it in 1 quarter. The position peaked at $285K in Q3 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 99,566 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $285K.
  • Advantage Alpha Capital Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $285K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.